GlassScriptPhysician profile
William G Irr
NPI 1801858097
$32,507.09
in general payments reported to CMS, 2019-2025
72 companies · $4,686 in 2025
The $4,686 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,563 · 2020: $3,357 · 2021: $5,113 · 2022: $4,577 · 2023: $4,597 · 2024: $5,615 · 2025: $4,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,897.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,012.18 | 2019-2025 | |
| Ucb, INC. | $1,950.55 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Biogen, INC. | $1,864.87 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Sk Life Science, INC. | $1,781.66 | 2020-2025 | Xcopri |
| Amgen INC. | $1,769.31 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $1,722.50 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genentech USA, INC. | $1,452.58 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $1,239.57 | 2019-2025 | |
| Lilly USA, LLC | $1,228.86 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $1,102.05 | 2019-2025 | Ingrezza, Ongentys |
| Grifols USA, LLC | $1,070.80 | 2019-2025 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $1,066.28 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $905.87 | 2019-2025 | |
| Lundbeck LLC | $830.72 | 2020-2025 | Vyepti, Rexulti |
| Pfizer INC. | $805.62 | 2022-2025 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Irr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.